NEW YORK (AP) -- Shares of Stemline Therapeutics rose Tuesday after the company reported some data from a treatment for brain cancer.

The New York company said it will report results from a mid-stage clinical trial of SL-701 as a treatment for high-grade glioma, a type of cancer that starts in the brain or spine, at a meeting of the Society for Neuro-Oncology in San Francisco that runs from Thursday to Sunday.

Stemline Therapeutics said SL-701 caused "specific and sustained immune responses against its brain tumor targets," and it said patients who had an immune system response had better profession free-survival. That means the patients lived longer prior to death or the resumption of disease progression.

Stemline will also present data from a study involving adult patients with newly-diagnosed or recurrent low-grade glioma.

Stemline Therapeutics Inc. is development-stage company studying drugs that target cancer stem cells, the cells from which tumors grow. Its shares picked up 20 cents to $20.15.